126
|
Ko D, You J, Chung Y, Park Y, Park I. 4 The Usefulness of Bedside Ultrasonography for Acute Epiglottitis in Emergency Department: Preliminary Study. Ann Emerg Med 2011. [DOI: 10.1016/j.annemergmed.2011.06.029] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
127
|
You J, Chung Y, Chung S, Park I, Kim S. 277 Liver Trauma Diagnosis With Contrast-Enhanced Ultrasound: Interobserver Variability between Radiologist and Emergency Physician in an Animal Study. Ann Emerg Med 2011. [DOI: 10.1016/j.annemergmed.2011.06.307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
128
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Angerami A, Aoki K, Apadula N, Aphecetche L, Aramaki Y, Asai J, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Basye AT, Bathe S, Batsouli S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bhom JH, Bickley AA, Blau DS, Boissevain JG, Bok JS, Borel H, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Caringi A, Chang BS, Chang WC, Charvet JL, Chen CH, Chernichenko S, Chi CY, Chiu M, Choi IJ, Choi JB, Choudhury RK, Christiansen P, Chujo T, Chung P, Churyn A, Chvala O, Cianciolo V, Citron Z, Cole BA, Conesa del Valle Z, Connors M, Constantin P, Csanád M, Csörgo T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, David G, Dayananda MK, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dharmawardane KV, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Dubey AK, Durham JM, Durum A, Dutta D, Dzhordzhadze V, D'Orazio L, Edwards S, Efremenko YV, Ellinghaus F, Engelmore T, Enokizono A, En'yo H, Esumi S, Eyser KO, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grim G, Grosse Perdekamp M, Gunji T, Gustafsson HÅ, Hadj Henni A, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Han R, Hanks J, Hartouni EP, Haruna K, Haslum E, Hayano R, He X, Heffner M, Hemmick TK, Hester T, Hill JC, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Iinuma H, Ikeda Y, Imai K, Imrek J, Inaba M, Isenhower D, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Iwanaga Y, Jacak BV, Jia J, Jiang X, Jin J, Johnson BM, Jones T, Joo KS, Jouan D, Jumper DS, Kajihara F, Kametani S, Kamihara N, Kamin J, Kang JH, Kapustinsky J, Karatsu K, Kasai M, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kikuchi J, Kim A, Kim BI, Kim DH, Kim DJ, Kim E, Kim EJ, Kim SH, Kim YJ, Kinney E, Kiriluk K, Kiss Á, Kistenev E, Klay J, Klein-Boesing C, Kochenda L, Komkov B, Konno M, Koster J, Kozlov A, Král A, Kravitz A, Kunde GJ, Kurita K, Kurosawa M, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Layton D, Lebedev A, Lee DM, Lee J, Lee KB, Lee KS, Lee T, Leitch MJ, Leite MAL, Lenzi B, Li X, Lichtenwalner P, Liebing P, Linden Levy LA, Liška T, Litvinenko A, Liu H, Liu MX, Love B, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mannel E, Mao Y, Mašek L, Masui H, Matathias F, McCumber M, McGaughey PL, McGlinchey D, Means N, Meredith B, Miake Y, Mibe T, Mignerey AC, Mikeš P, Miki K, Milov A, Mishra M, Mitchell JT, Mohanty AK, Moon HJ, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Mukhopadhyay D, Murakami T, Murata J, Nagamiya S, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura KR, Nakamura T, Nakano K, Nam S, Newby J, Nguyen M, Nihashi M, Niita T, Nouicer R, Nyanin AS, Oakley C, O'Brien E, Oda SX, Ogilvie CA, Oka M, Okada K, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Palounek APT, Pantuev V, Papavassiliou V, Park IH, Park J, Park SK, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Petti R, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reygers K, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rosen CA, Rosendahl SSE, Rosnet P, Rukoyatkin P, Ružička P, Rykov VL, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakashita K, Samsonov V, Sano S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Semenov V, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Slunečka M, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sukhanov A, Sziklai J, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Taneja S, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarján P, Themann H, Thomas D, Thomas TL, Togawa M, Toia A, Tomášek L, Tomita Y, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Vinogradov AA, Virius M, Vossen A, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Wei F, Wei R, Wessels J, White SN, Winter D, Woody CL, Wright RM, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Ying J, Yokkaichi S, You Z, Young GR, Younus I, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zolin L. Cold nuclear matter effects on J/ψ yields as a function of rapidity and nuclear geometry in d+A collisions at sqrt[s(NN)]=200 GeV. PHYSICAL REVIEW LETTERS 2011; 107:142301. [PMID: 22107186 DOI: 10.1103/physrevlett.107.142301] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/07/2010] [Indexed: 05/31/2023]
Abstract
We present measurements of J/ψ yields in d+Au collisions at sqrt[s(NN)]=200 GeV recorded by the PHENIX experiment and compare them with yields in p+p collisions at the same energy per nucleon-nucleon collision. The measurements cover a large kinematic range in J/ψ rapidity (-2.2<y<2.4) with high statistical precision and are compared with two theoretical models: one with nuclear shadowing combined with final state breakup and one with coherent gluon saturation effects. In order to remove model dependent systematic uncertainties we also compare the data to a simple geometric model. The forward rapidity data are inconsistent with nuclear modifications that are linear or exponential in the density weighted longitudinal thickness, such as those from the final state breakup of the bound state.
Collapse
|
129
|
Park I, Lee K, Sun H, Kim S, Lee J, Jeon G. High accuracy predictions of IVF prognosis attained using a combination of AMH and day 3 FSH/LH ratio. Fertil Steril 2011. [DOI: 10.1016/j.fertnstert.2011.07.738] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
130
|
Park I, Park RW, Lim SK, Lee W, Shin JS, Yu S, Shin GT, Kim H. Rectal culture screening for vancomycin-resistant enterococcus in chronic haemodialysis patients: false-negative rates and duration of colonisation. J Hosp Infect 2011; 79:147-50. [PMID: 21764175 DOI: 10.1016/j.jhin.2011.04.011] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2010] [Accepted: 04/08/2011] [Indexed: 10/18/2022]
Abstract
Infection or colonisation with vancomycin-resistant enterococci (VRE) is common in chronic haemodialysis (HD) patients. However, there is limited information on the duration of VRE colonisation or on the reliability of consecutive negative rectal cultures to determine the clearance of VRE in chronic HD patients. Chronic HD patients from whom VRE was isolated were examined retrospectively. Rectal cultures were collected more than three times, at least one week apart, between 1 June 2003 and 1 March 2010. The results of the sequential VRE cultures and patients' data were analysed. Among 812 patients from whom VRE was isolated, 89 were chronic HD patients and 92 had three consecutive negative cultures. It took 60.7 ± 183.9 and 111.4 ± 155.4 days to collect three consecutive negative cultures in the 83 non-chronic haemodialysis patients and nine chronic HD patients, respectively (P = 0.011). The independent risk factors for more than three negative sequential rectal cultures were glycopeptide usage [odds ratio (OR): 2.155; P = 0.003] and length of hospital stay (OR: 1.009; P = 0.001). After three consecutive negative rectal cultures, two of six chronic HD patients and 10 of 36 non-HD patients were culture positive again. In conclusion, a significant proportion of patients colonised with VRE cannot be detected by three-weekly rectal cultures, and the duration of VRE colonisation in chronic haemodialysis patients tends to be prolonged. These results may be contributing to the continued increase in the prevalence of VRE.
Collapse
|
131
|
Howard H, Barandas A, Creegan L, Bauer H, Chow J, Park I, Bolan G. P5-S3.01 Developing a multi-pronged quality improvement (QI) strategy to increase Chlamydia trachomatis (CT) retesting rates: building a framework for success. Br J Vener Dis 2011. [DOI: 10.1136/sextrans-2011-050108.537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
132
|
Park I, Lee J, Ahn J, Lee D, Song C, Hong J, Kim C, Ahn H. Prognostic factors and survial of advanced renal cell carcinoma with predominant sarcomatoid histology. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
400 Background: Sarcomatoid renal cell carcinoma (SRCC) is known to have aggressive clinical course and poor response to treatment. Very limited data of clinical feature, prognostic factor, and survival are available for advanced disease with predominant sarcomatoid histology. We evaluated clinical features, response to treatment, and prognostic factors for survival. Methods: Between 2001 and 2010, 30 patients with metastatic or recurrent RCC with predominant sarcomatoid histology (sarcomatoid component 30% or more for resected kidney or exclusive sarcomatoid carcinoma on needle biopsy) were treated at our institution. We reviewed these patients' records to identify clinical and pathologic features which could affect survival. The role of nephrectomy and systemic therapy on patient outcome was also investigated. Results: There were 20 male and 10 female patients with a median age of 58 years (range, 43–83). Twenty patients had initially metastatic disease and 16 patients (53%) had ECOG performance status (PS) of 0–1. The most frequent metastatic site was lung (57%) followed by bone (43%) and distant lymph nodes (23%). Fourteen (70%) out of 20 patients with initially metastatic disease underwent primary nephrectomy and six patients also underwent metastasectomy. The median % of sarcomatoid component was 80% (range, 30–100%). All patients (N=10) who received immunotherapy had progressive disease as their best response and only one out of 5 patients treated with sunitinib or everolimus had a partial response. With a median follow-up duration of 22 months, the median survival was 3.6 months (95% CI, 0∼7.5) with 6-month survival rate of 43%. Only ECOG PS had impact on survival (P<0.001: ECOG=0, 14.1 months; ECOG=1, 7.4 months; ECOG=2, 3.2 months, and ECOG=3, 1.64 months). Survivals for initially metastatic disease were not significantly different whether patients underwent nephrectomy or not (2.0 months vs. 3.4 months, HR=0.62, 95% CI, 0.16–2.44 after correcting for potential prognostic factors). Conclusions: Patients with SRCC have a fulminant clinical course and the majority of patients had disease progression irrespective of any treatment. Only performance status dose have impact on overall survival. No significant financial relationships to disclose.
Collapse
|
133
|
Park I, Moon E, Hwang JA, Yu S, Kim BW, Wang HJ, Shin GT, Kim H. Does hepatorenal syndrome affect the result of liver transplantation? Clinical observations. Transplant Proc 2011; 42:2563-6. [PMID: 20832544 DOI: 10.1016/j.transproceed.2010.04.049] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2009] [Revised: 10/13/2009] [Accepted: 04/21/2010] [Indexed: 12/01/2022]
Abstract
Hepatorenal syndrome (HRS) is a reversible, functional renal failure that occurs in patients with advanced hepatic failure. However, the reported rates of complete recovery of renal function and patient survivals after orthotopic liver transplantation (OLT) are variable. The aim of this study was to compare the outcomes after OLT between patients with HRS and those without HRS (no-HRS). We established exclusion criteria to select study patients who underwent OLT in a single center between January 2005 and October 2008. The exclusion criteria included the following: (1) malignancy, (2) <18 years of age, (3) other than primary OLT, (4) ABO mismatch or hemophilia, (5) no liver cirrhosis, and (6) survival >1 month after OLT. We selected 71 subjects, including 8 HRS and 63 no-HRS patients. No significant differences were observed in the estimated glomerular filtration rate (eGFR) between the 2 groups except for a lower eGFR on the day of and 1 month after OLT in the HRS group: 108.3 ± 40.5 versus 31.4 ± 14.1 mL/min and 85.4 ± 15.0 versus 57.3 ± 12.1 mL/min (P = .000 and P = .014, respectively). The renal function of 6/7 HRS patients who survived >1 year improved. The 1-year patient survival rate after OLT in HRS patients was similar to that without HRS: 95% versus 86% (P = .37). We concluded that HRS had minimal effects on patient survival and return of acceptable renal function.
Collapse
|
134
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Akimoto R, Alexander J, Al-Ta'ani H, Andrews KR, Angerami A, Aoki K, Apadula N, Appelt E, Aramaki Y, Armendariz R, Aschenauer EC, Awes TC, Azmoun B, Babintsev V, Bai M, Bannier B, Barish KN, Bassalleck B, Basye AT, Bathe S, Baublis V, Baumann C, Bazilevsky A, Belmont R, Ben-Benjamin J, Bennett R, Berdnikov A, Berdnikov Y, Blau DS, Bok JS, Boyle K, Brooks ML, Broxmeyer D, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Campbell S, Caringi A, Castera P, Chen CH, Chi CY, Chiu M, Choi IJ, Choi JB, Choudhury RK, Christiansen P, Chujo T, Chvala O, Cianciolo V, Citron Z, Cole BA, Conesa del Valle Z, Connors M, Csanád M, Csörgo T, Dairaku S, Datta A, David G, Dayananda MK, Denisov A, Deshpande A, Desmond EJ, Dharmawardane KV, Dietzsch O, Dion A, Donadelli M, D'Orazio L, Drapier O, Drees A, Drees KA, Durham JM, Durum A, Efremenko YV, Engelmore T, Enokizono A, En'yo H, Esumi S, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Frantz JE, Franz A, Frawley AD, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong X, Gonin M, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Guo L, Gustafsson HÅ, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Hanks J, Han R, Harper C, Hashimoto K, Haslum E, Hayano R, Hemmick TK, Hester T, He X, Hill JC, Hollis RS, Holzmann W, Homma K, Hong B, Horaguchi T, Hori Y, Hornback D, Huang S, Ichihara T, Ichimiya R, Iinuma H, Ikeda Y, Imai K, Inaba M, Iordanova A, Isenhower D, Ishihara M, Issah M, Isupov A, Ivanischev D, Iwanaga Y, Jacak BV, Jia J, Jiang X, Johnson BM, Jones T, Joo KS, Jouan D, Kamin J, Kaneti S, Kang BH, Kang JH, Kang JS, Kapustinsky J, Karatsu K, Kasai M, Kawall D, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kim BI, Kim DJ, Kim EJ, Kim YJ, Kim YK, Kinney E, Kiss Á, Kistenev E, Kleinjan D, Kline P, Kochenda L, Komkov B, Konno M, Koster J, Kotov D, Král A, Kunde GJ, Kurita K, Kurosawa M, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Lee DM, Lee J, Lee KB, Lee KS, Lee SH, Lee SR, Leitch MJ, Leite MAL, Lichtenwalner P, Lim SH, Linden Levy LA, Litvinenko A, Liu H, Liu MX, Li X, Love B, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Manion A, Manko VI, Mannel E, Mao Y, Masui H, McCumber M, McGaughey PL, McGlinchey D, McKinney C, Means N, Mendoza M, Meredith B, Miake Y, Mibe T, Mignerey AC, Miki K, Milov A, Mitchell JT, Miyachi Y, Mohanty AK, Moon HJ, Morino Y, Morreale A, Morrison DP, Motschwiller S, Moukhanova TV, Murakami T, Murata J, Nagamiya S, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura KR, Nakamura T, Nakano K, Newby J, Nguyen M, Nihashi M, Nouicer R, Nyanin AS, Oakley C, O'Brien E, Ogilvie CA, Okada K, Oka M, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park BH, Park IH, Park SK, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Petti R, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Qu H, Rak J, Ravinovich I, Read KF, Reygers K, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rosendahl SSE, Rukoyatkin P, Sahlmueller B, Saito N, Sakaguchi T, Samsonov V, Sano S, Sarsour M, Sato T, Savastio M, Sawada S, Sedgwick K, Seidl R, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shim HH, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Slunečka M, Sodre T, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Stankus PW, Stenlund E, Stoll SP, Sugitate T, Sukhanov A, Sun J, Sziklai J, Takagui EM, Takahara A, Taketani A, Tanabe R, Tanaka Y, Taneja S, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tennant E, Themann H, Thomas D, Togawa M, Tomášek L, Tomášek M, Torii H, Towell RS, Tserruya I, Tsuchimoto Y, Utsunomiya K, Vale C, van Hecke HW, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Virius M, Vossen A, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Watanabe YS, Wei F, Wei R, Wessels J, White SN, Winter D, Woody CL, Wright RM, Wysocki M, Yamaguchi YL, Yang R, Yanovich A, Ying J, Yokkaichi S, Yoo JS, Young GR, Younus I, You Z, Yushmanov IE, Zajc WA, Zelenski A, Zhou S, Zolin L. Cross section and parity-violating spin asymmetries of W± boson production in polarized p + p collisions at sqrt[s] = 500 GeV. PHYSICAL REVIEW LETTERS 2011; 106:062001. [PMID: 21405459 DOI: 10.1103/physrevlett.106.062001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/03/2010] [Indexed: 05/30/2023]
Abstract
Large parity-violating longitudinal single-spin asymmetries A(L)(e+) = -0.86(-0.14) (+0.30) and A(L)(e-) = 0.88(-0.71) (+0.12) are observed for inclusive high transverse momentum electrons and positrons in polarized p+p collisions at a center-of-mass energy of sqrt[s] = 500 GeV with the PHENIX detector at RHIC. These e± come mainly from the decay of W± and Z0 bosons, and their asymmetries directly demonstrate parity violation in the couplings of the W± to the light quarks. The observed electron and positron yields were used to estimate W± boson production cross sections for the e± channels of σ(pp → W+ X) × BR(W+ → e+ ν(e)) = 144.1 ± 21.2(stat)(-10.3) (+3.4) (syst) ± 21.6(norm) pb, and σ(pp → W- X) × BR(W- → e- ν[over ¯](e)) = 31.7 ± 12.1(stat)(-8.2) (+10.1) (syst) ± 4.8(norm) pb.
Collapse
|
135
|
Park IH, Ku J, Lee H, Kim SY, Kim SI, Yoon KJ, Kim JJ. Disrupted theory of mind network processing in response to idea of reference evocation in schizophrenia. Acta Psychiatr Scand 2011; 123:43-54. [PMID: 20712827 DOI: 10.1111/j.1600-0447.2010.01597.x] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVE This study examined the neural pathophysiology of the theory of mind network by eliciting self-referential processing during an idea of reference evocating situation in patients with schizophrenia. METHOD Functional MRI was conducted on 14 schizophrenic in-patients with the idea of reference and 15 healthy participants while viewing video vignettes of referential conversations, non-referential conversations or no conversations between two people, which were filmed at varying distances of 1, 5 or 10 m. RESULTS The patient group did not show normal patterns of superior temporal sulcus activation to conversational context, and reciprocal deactivation and activation of the ventromedial and dorsomedial prefrontal cortex to referential conversational context. Instead, the patient group showed overall greater ventromedial prefrontal activities across different conversational contexts and inverse correlation between superior temporal sulcus activity and delusional severity. Differential activations of the temporal pole and its posterior extension to varying distances were observed in the control group but not in the patient group. CONCLUSION The present study demonstrates that theory of mind-related responses of the medial prefrontal-superior temporal network are attenuated during the self-referential processing in patients with schizophrenia and that these abnormalities may be related to the formation of their referential or persecutory delusion.
Collapse
|
136
|
Jung SY, Kwon Y, Kim EA, Ko KL, Shin KH, Lee KS, Park IH, Lee S, Kim SW, Kang HS, Ro J. Abstract P4-09-14: Invasive Lobular Carcinoma Is a Prototype of Luminal A Breast Cancer Subtype and Rare in Korea. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p4-09-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose Invasive lobular carcinoma (ILC) is known to be the second most frequent histologic subtype, occupying 10% of invasive breast cancer in the Western countries. The present study was designed to assess the clinical characteristics and outcomes of ILC compared to general invasive ductal carcinoma (IDC) and the luminal A subtype (LA-IDC).
Methods The study population included d 2916 patients with invasive breast cancer consecutively diagnosed at the National Cancer Center, Korea between 2001 and 2008. The clinicopathological characteristics and clinical outcomes were retrospectively reviewed.
Results There were 83 pts (2.8%) diagnosed with ILC and 1,088 pts (37.3%) with LA-IDC. Mean age was 48.2 years of all patients, 48.3 years of ILC group and 47.9 years of LA-IDC group. The ILC patients presented with a larger tumor size (≥T2, 59.8% vs. 38.8%, P=0.001), lower histologic grade (HG 1 or 2, 90.4% vs 64.4%, P<0.001), more often estrogen receptor (ER) and progesterone receptor (PgR) positivity (ER+, 90.4% vs. 64.4%, P<0.001; PgR+, 71.1% vs. 50.1%, P<0.001), HER2 negativity (97.5% vs. 74.9%, P<0.001), lower Ki-67 expression (10.3% ± 10.6% vs. 20.6% ± 19.8%, P<0.001), and luminal A subtypes (91.4% vs. 51.2%, P<0.001) compared to the IDC group. Six (7.2%) ILC patients and 359 (12.7%) IDC patients developed disease recurrence with a median follow-up of 56.4 months (range 4.9-136.6 months). Although ILC showed similar prognosis to IDC in general (5-year DFS rate, 91.7% in ILC vs. 87.4% in IDC, P=0.31; 5-year OS rate, 93.6% in ILC vs. 92.5% in IDC, P=0.38), its outcome was closer to LA-IDC, and better than non LA-IDC (LA-IDC (ref); ILC, HR 0.77 in recurrence, 95% CI 0.31-1.90, P=0.57; HR 0.75 in death, 95% CI 0.18-3.09, P=0.70; non LA-IDC, HR 1.69 in recurrence, 95% CI 1.23-2.33, P=0.001; HR 1.50 in death, 95% CI 0.97-2.33, P=0.07) in univariate and multivariate analysis.
Conclusions ILC is a very rare histologic subtype of breast cancer in Korea compared to the Western countries and has distinctive clinicopathological characteristics similar to those of LA-IDC. Acknowledgement: supported by NCC grant #0910320
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P4-09-14.
Collapse
|
137
|
Jung SY, Kim SK, Kwon Y, Kim EA, Ko KL, Park IH, Lee KS, Kang KW, Noh DY, Shin SH, Jeong JS, Lee S, Kim SW, Kang HS, Ro J. Abstract P2-09-01: Serial [18F] FDG-PET after the 2nd Cycle of Preoperative Chemotherapy Is Predictive for Pathological Complete Response in Stage II/III Breast Cancer. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p2-09-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose: One of substudies of the prospective trials aimed to evaluate the usefulness of serial [18F] 2-fluoro-2-deoxy-D-glucose-positron emission tomography ([18F] FDG-PET) for predicting pathological complete response (pCR) in stage II/III breast cancer with preoperative chemotherapy (PST).
Methods: Serial PET was undertaken in 57 breast cancer patients enrolled in three different neoadjuvant trials: 35 patients from a phase II study with paclitaxel/gemcitabine/trastuzumab with ClinicalTrial.gov NCT 00532857, 9 patients from a phase Ib study with paclitaxel/gemcitabine/lapatinib with ClinicalTrial.gov NCT 01133912, and 13 patients from a phase Ib with paclitaxel/gemcitabine/sunitinib with ClinicalTrial.gov NCT0 1070706. All patients received 6 cycles of PST followed by surgery and radiotherapy. We assessed the peak standardized uptake value (SUVp) in the primary tumor at the baseline and after the 2nd cycle (37 patients) or after completion (20 patients) of 6 cycles of PST, and calculated the reduction rate (RR) of the SUVp. Pathological response was classified into pCR and non-pCR. To compare the mean of SUVp and RR of SUVp between different response groups, two-way tables and chi-square tests were used
Results: Fifteen (40.6%) of 37 patients who took repeat PET after the 2nd PST and 15 (75%) of 20 patients after completion of PST achieved a pCR with overall pCR rate of 52.6% in the primary tumor. In patients with repeat PET after the 2nd PST, post-treatment SUVp and RR of the SUVp in primary tumors were significantly different by the pathological response (post-treatment SUVp, 1.54 ± 0.63 in pCR vs 2.54 ± 1.06 in non-pCR, P=0.002; RR of the SUVp, 79.2% ± 11.9% in pCR vs 68.9% ± 15.4% in non-pCR, P=0.03). However, in patients with repeat PET after completion of PST, there were no statistical differences of these values (post-treatment SUVp, 1.09 ± 0.63 in pCR vs 1.29 ± 0.36 in non-pCR, P=0.42; RR of the SUVp, 83.7% ± 14.0% in pCR vs 67.5% ± 21.1% in non-pCR, P=0.17)
Conclusions: This study demonstrated that repeat PET after the 2nd cycle of PST, not after completion of PST could predict pCR in stage II/III breast cancer with preoperative chemotherapy. Acknowledgement NCC Grant #0910320.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-09-01.
Collapse
|
138
|
Ellingson BM, Pope WB, Lai A, Nghiemphu PL, Cloughesy TF, Juhasz C, Mittal S, Muzik O, Chugani DC, Chakraborty PK, Bahl G, Barger GR, Carrillo JA, Lai A, Nghiemphu P, Tran A, Moftakhar P, Cloughesy TF, Pope WB, Bruggers C, Moore K, Khatua S, Gumerlock MK, Stolzenberg E, Fung KM, Smith ML, Kedzierska K, Chacko G, Epstein RB, Holter J, Parvataneni R, Kadambi A, Park I, Elkhaled A, Essock-Burns E, Khayal I, Butowski N, Lamborn K, Chang S, Nelson S, Sanverdi E, Ozgen B, Oguz KK, Soylemezoglu F, Mut M, Zhu JJ, Pfannl R, Do-Dai D, Yao K, Mignano J, Wu JK, Linendoll N, Beal K, Chan T, Yamamda Y, Holodny A, Gutin PH, Zhang Z, Young RJ, Lupo JM, Essock-Burns E, Cha S, Chang SM, Butowski N, Nelson SJ, Laperriere N, Perry J, Macdonald D, Mason W, Easaw J, Del Maestro R, Kucharczyk W, Hussey D, Greaves K, Moore S, Pouliot JF, Rauschkolb PK, Smith SD, Belden CJ, Lallana EC, Fadul CE, Bosscher L, Slot M, Sanchez E, Uitdehaag BM, Vandertop WP, Peerdeman SM, Blumenthal DT, Bokstein F, Artzi M, Palmon M, Aizenstein O, Sitt R, Gurevich K, Kanner A, Ram Z, Corn B, Ben Bashat D, Slot M, Bosscher L, Sanchez E, Uitdehaag BM, Vandertop WP, Peerdeman SM, Martinez N, Gorniak R, Tartaglino L, Scanlan M, Glass J, Kleijn A, Chen JW, Sun PZ, Buhrman J, Rabkin SD, Weissleder R, Martuza RL, Lamfers ML, Fulci G, Lallana EC, Brong KA, Hekmatyar K, Jerome N, Wilson M, Fadul CE, Kauppinen RA, Mok K, Valenca MM, Sherafat E, Olivier A, Pentsova E, Rosenblum M, Holodny A, Palomba L, Omuro A, Murad GJ, Yachnis AT, Dunbar EM, Essock-Burns E, Li Y, Lupo J, Polley MY, Butowski N, Cha S, Chang S, Nelson S, Kohler N, Quisling R, Dunbar EM, Swanson KR, Gu S, Chakraborty G, Alessio A, Claridge J, Rockne RC, Muzi M, Krohn KA, Spence AM, Alvord EC, Anderson AR, Kinahan P, Boone AE, Rockne RC, Mrugala MM, Swanson KR, Gutova M, Khankaldyyan V, Herrmann KA, Harutyunyan I, Abramyants Y, Annala AJ, Najbauer J, Moats RA, Shackleford GM, Barish ME, Aboody KS. Radiology. Neuro Oncol 2010. [DOI: 10.1093/neuonc/noq116.s17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
139
|
Bratcher PE, Park IH, Oliver MB, Hortal M, Camilli R, Hollingshead SK, Camou T, Nahm MH. Evolution of the capsular gene locus of Streptococcus pneumoniae serogroup 6. MICROBIOLOGY-SGM 2010; 157:189-198. [PMID: 20929956 PMCID: PMC3068628 DOI: 10.1099/mic.0.043901-0] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Streptococcus pneumoniae expressing serogroup 6 capsules frequently causes pneumococcal infections and the evolutionary origins of the serogroup 6 strains have been extensively studied. However, these studies were performed when serogroup 6 had only two known members (serotypes 6A and 6B) and before the two new members (serotypes 6C and 6D) expressing wciNβ were found. We have therefore reinvestigated the evolutionary origins of serogroup 6 by examining the profiles of the capsule gene loci and the multilocus sequence types (MLSTs) of many serogroup 6 isolates from several continents. We confirmed that there are two classes of cps locus sequences for serogroup 6 isolates. In our study, class 2 cps sequences were limited to a few serotype 6B isolates. Neighbour-joining analysis of cps sequence profiles showed a distinct clade for 6C and moderately distinct clades for class 1 6A and 6B sequences. The serotype 6D cps profile was found within the class 1 6B clade, suggesting that it was created by recombination between 6C and 6B cps loci. Interestingly, all 6C isolates also had a unique wzy allele with a 6 bp deletion. This suggests that serotype switching to 6C involves the transfer of a large (>4 kb) gene segment that includes both the wciNβ allele and the ‘short’ wzy allele. The MLST studies of serotype 6C isolates suggest that the 6C cps locus is incorporated into many different pneumococcal genomic backgrounds but that, interestingly, 6C cps may have preferentially entered strains of the same genomic backgrounds as those of serotype 6A.
Collapse
|
140
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Aoki K, Aramaki Y, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Barish KN, Bassalleck B, Basye AT, Bathe S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bickley AA, Bok JS, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Chen CH, Chi CY, Chiu M, Choi IJ, Choudhury RK, Christiansen P, Chujo T, Chung P, Chvala O, Cianciolo V, Citron Z, Cole BA, Connors M, Constantin P, Csanád M, Csörgo T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, David G, Denisov A, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Durham JM, Durum A, Dutta D, Edwards S, Efremenko YV, Ellinghaus F, Engelmore T, Enokizono A, En'yo H, Esumi S, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong H, Gonin M, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HÅ, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Hanks J, Han R, Hartouni EP, Haslum E, Hayano R, Heffner M, Hegyi S, Hemmick TK, Hester T, He X, Hill JC, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Ide J, Ikeda Y, Imai K, Inaba M, Isenhower D, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Jacak BV, Jia J, Jin J, Johnson BM, Joo KS, Jouan D, Jumper DS, Kajihara F, Kametani S, Kamihara N, Kamin J, Kang JH, Kapustinsky J, Karatsu K, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kim BI, Kim DH, Kim DJ, Kim EJ, Kim E, Kim SH, Kim YJ, Kinney E, Kiriluk K, Kiss A, Kistenev E, Kochenda L, Komkov B, Konno M, Koster J, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kunde GJ, Kurita K, Kurosawa M, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Lee DM, Lee J, Lee KB, Lee K, Lee KS, Leitch MJ, Leite MAL, Leitner E, Lenzi B, Liebing P, Linden Levy LA, Liška T, Litvinenko A, Liu H, Liu MX, Li X, Love B, Luechtenborg R, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mannel E, Mao Y, Masui H, Matathias F, McCumber M, McGaughey PL, Means N, Meredith B, Miake Y, Mignerey AC, Mikeš P, Miki K, Milov A, Mishra M, Mitchell JT, Mohanty AK, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Murata J, Nagamiya S, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Nouicer R, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Okada K, Oka M, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park IH, Park J, Park SK, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Reygers K, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rosen CA, Rosendahl SSE, Rosnet P, Rukoyatkin P, Ružička P, Sahlmueller B, Saito N, Sakaguchi T, Sakashita K, Samsonov V, Sano S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Slunečka M, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Sparks NA, Stankus PW, Stenlund E, Stoll SP, Sugitate T, Sukhanov A, Sziklai J, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarján P, Themann H, Thomas TL, Togawa M, Toia A, Tomášek L, Torii H, Towell RS, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Wei F, Wei R, Wessels J, White SN, Winter D, Wood JP, Woody CL, Wright RM, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Ying J, Yokkaichi S, Young GR, Younus I, You Z, Yushmanov IE, Zajc WA, Zhang C, Zhou S, Zolin L. Azimuthal anisotropy of π⁰ production in Au+Au collisions at sqrt((s)NN)=200 GeV: path-length dependence of jet quenching and the role of initial geometry. PHYSICAL REVIEW LETTERS 2010; 105:142301. [PMID: 21230825 DOI: 10.1103/physrevlett.105.142301] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/18/2010] [Indexed: 05/30/2023]
Abstract
We have measured the azimuthal anisotropy of π⁰ production for 1<p(T)<18 GeV/c for Au+Au collisions at sqrt((s)NN)=200 GeV. The observed anisotropy shows a gradual decrease for 3≲p(T)≲7-10 GeV/c, but remains positive beyond 10 GeV/c. The magnitude of this anisotropy is underpredicted, up to at least ∼10 GeV/c, by current perturbative QCD (PQCD) energy-loss model calculations. An estimate of the increase in anisotropy expected from initial-geometry modification due to gluon saturation effects and fluctuations is insufficient to account for this discrepancy. Calculations that implement a path-length dependence steeper than what is implied by current PQCD energy-loss models show reasonable agreement with the data.
Collapse
|
141
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Aoki K, Aramaki Y, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Barish KN, Bassalleck B, Basye AT, Bathe S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bickley AA, Bok JS, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Chen CH, Chi CY, Chiu M, Choi IJ, Choudhury RK, Christiansen P, Chujo T, Chung P, Chvala O, Cianciolo V, Citron Z, Cole BA, Connors M, Constantin P, Csanád M, Csörgo T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, David G, Denisov A, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Durham JM, Durum A, Dutta D, Edwards S, Efremenko YV, Ellinghaus F, Engelmore T, Enokizono A, En'yo H, Esumi S, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong H, Gonin M, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HA, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Hanks J, Han R, Hartouni EP, Haslum E, Hayano R, Heffner M, Hegyi S, Hemmick TK, Hester T, He X, Hill JC, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Ide J, Ikeda Y, Imai K, Inaba M, Isenhower D, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Jacak BV, Jia J, Jin J, Johnson BM, Joo KS, Jouan D, Jumper DS, Kajihara F, Kametani S, Kamihara N, Kamin J, Kang JH, Kapustinsky J, Karatsu K, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kim BI, Kim DH, Kim DJ, Kim EJ, Kim E, Kim SH, Kim YJ, Kinney E, Kiriluk K, Kiss A, Kistenev E, Kochenda L, Komkov B, Konno M, Koster J, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kunde GJ, Kurita K, Kurosawa M, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Lebedev A, Lee DM, Lee J, Lee KB, Lee K, Lee KS, Leitch MJ, Leite MAL, Leitner E, Lenzi B, Liebing P, Linden Levy LA, Liska T, Litvinenko A, Liu H, Liu MX, Li X, Love B, Luechtenborg R, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mannel E, Mao Y, Masui H, Matathias F, McCumber M, McGaughey PL, Means N, Meredith B, Miake Y, Mignerey AC, Mikes P, Miki K, Milov A, Mishra M, Mitchell JT, Mohanty AK, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Murata J, Nagamiya S, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Nouicer R, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Okada K, Oka M, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Pantuev V, Papavassiliou V, Park IH, Park J, Park SK, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Reygers K, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rosen CA, Rosendahl SSE, Rosnet P, Rukoyatkin P, Ruzicka P, Sahlmueller B, Saito N, Sakaguchi T, Sakashita K, Samsonov V, Sano S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Slunecka M, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Sparks NA, Stankus PW, Stenlund E, Stoll SP, Sugitate T, Sukhanov A, Sziklai J, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarján P, Themann H, Thomas TL, Togawa M, Toia A, Tomásek L, Torii H, Towell RS, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Wei F, Wei R, Wessels J, White SN, Winter D, Wood JP, Woody CL, Wright RM, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Ying J, Yokkaichi S, Young GR, Younus I, You Z, Yushmanov IE, Zajc WA, Zhang C, Zhou S, Zolin L. Elliptic and hexadecapole flow of charged hadrons in Au+Au collisions at sq.rt(s(NN))=200 GeV. PHYSICAL REVIEW LETTERS 2010; 105:062301. [PMID: 20867976 DOI: 10.1103/physrevlett.105.062301] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/29/2010] [Indexed: 05/29/2023]
Abstract
Differential measurements of the elliptic (v(2)) and hexadecapole (v(4)) Fourier flow coefficients are reported for charged hadrons as a function of transverse momentum (p(T)) and collision centrality or number of participant nucleons (N(part)) for Au+Au collisions at sq.rt(s(NN))=200 GeV. The v(2,4) measurements at pseudorapidity |η|≤0.35, obtained with four separate reaction-plane detectors positioned in the range 1.0<|η|<3.9, show good agreement, indicating the absence of significant Δη-dependent nonflow correlations. Sizable values for v(4)(p(T)) are observed with a ratio v(4)(p(T),N(part))/v(2)(2)(p(T),N(part))≈0.8 for 50≲N(part)≲200, which is compatible with the combined effects of a finite viscosity and initial eccentricity fluctuations. For N(part)≳200 this ratio increases up to 1.7 in the most central collisions.
Collapse
|
142
|
Adare A, Afanasiev S, Aidala C, Ajitanand NN, Akiba Y, Al-Bataineh H, Alexander J, Aoki K, Aphecetche L, Aramaki Y, Asai J, Atomssa ET, Averbeck R, Awes TC, Azmoun B, Babintsev V, Bai M, Baksay G, Baksay L, Baldisseri A, Barish KN, Barnes PD, Bassalleck B, Basye AT, Bathe S, Batsouli S, Baublis V, Baumann C, Bazilevsky A, Belikov S, Belmont R, Bennett R, Berdnikov A, Berdnikov Y, Bickley AA, Boissevain JG, Bok JS, Borel H, Boyle K, Brooks ML, Buesching H, Bumazhnov V, Bunce G, Butsyk S, Camacho CM, Campbell S, Chang BS, Chang WC, Charvet JL, Chen CH, Chernichenko S, Chi CY, Chiu M, Choi IJ, Choudhury RK, Christiansen P, Chujo T, Chung P, Churyn A, Chvala O, Cianciolo V, Citron Z, Cole BA, Connors M, Constantin P, Csanád M, Csörgo T, Dahms T, Dairaku S, Danchev I, Das K, Datta A, David G, Denisov A, d'Enterria D, Deshpande A, Desmond EJ, Dietzsch O, Dion A, Donadelli M, Drapier O, Drees A, Drees KA, Dubey AK, Durham JM, Durum A, Dutta D, Dzhordzhadze V, Edwards S, Efremenko YV, Ellinghaus F, Engelmore T, Enokizono A, En'yo H, Esumi S, Eyser KO, Fadem B, Fields DE, Finger M, Finger M, Fleuret F, Fokin SL, Fraenkel Z, Frantz JE, Franz A, Frawley AD, Fujiwara K, Fukao Y, Fusayasu T, Garishvili I, Glenn A, Gong H, Gonin M, Gosset J, Goto Y, Granier de Cassagnac R, Grau N, Greene SV, Grosse Perdekamp M, Gunji T, Gustafsson HA, Hadj Henni A, Haggerty JS, Hahn KI, Hamagaki H, Hamblen J, Hanks J, Han R, Hartouni EP, Haruna K, Haslum E, Hayano R, Heffner M, Hegyi S, Hemmick TK, Hester T, He X, Hill JC, Hohlmann M, Holzmann W, Homma K, Hong B, Horaguchi T, Hornback D, Huang S, Ichihara T, Ichimiya R, Ide J, Iinuma H, Ikeda Y, Imai K, Imrek J, Inaba M, Isenhower D, Ishihara M, Isobe T, Issah M, Isupov A, Ivanischev D, Jacak BV, Jia J, Jin J, Johnson BM, Joo KS, Jouan D, Jumper DS, Kajihara F, Kametani S, Kamihara N, Kamin J, Kang JH, Kapustinsky J, Kawall D, Kawashima M, Kazantsev AV, Kempel T, Khanzadeev A, Kijima KM, Kikuchi J, Kim BI, Kim DH, Kim DJ, Kim EJ, Kim E, Kim SH, Kim YJ, Kinney E, Kiriluk K, Kiss A, Kistenev E, Klay J, Klein-Boesing C, Kochenda L, Komkov B, Konno M, Koster J, Kotchetkov D, Kozlov A, Král A, Kravitz A, Kunde GJ, Kurita K, Kurosawa M, Kweon MJ, Kwon Y, Kyle GS, Lacey R, Lai YS, Lajoie JG, Layton D, Lebedev A, Lee DM, Lee J, Lee KB, Lee K, Lee KS, Lee T, Leitch MJ, Leite MAL, Leitner E, Lenzi B, Liebing P, Linden Levy LA, Liska T, Litvinenko A, Liu H, Liu MX, Li X, Love B, Luechtenborg R, Lynch D, Maguire CF, Makdisi YI, Malakhov A, Malik MD, Manko VI, Mannel E, Mao Y, Masek L, Masui H, Matathias F, McCumber M, McGaughey PL, Means N, Meredith B, Miake Y, Mignerey AC, Mikes P, Miki K, Milov A, Mishra M, Mitchell JT, Mohanty AK, Morino Y, Morreale A, Morrison DP, Moukhanova TV, Mukhopadhyay D, Murata J, Nagamiya S, Nagle JL, Naglis M, Nagy MI, Nakagawa I, Nakamiya Y, Nakamura T, Nakano K, Newby J, Nguyen M, Niita T, Nouicer R, Nyanin AS, O'Brien E, Oda SX, Ogilvie CA, Okada K, Oka M, Onuki Y, Oskarsson A, Ouchida M, Ozawa K, Pak R, Palounek APT, Pantuev V, Papavassiliou V, Park IH, Park J, Park SK, Park WJ, Pate SF, Pei H, Peng JC, Pereira H, Peresedov V, Peressounko DY, Pinkenburg C, Pisani RP, Proissl M, Purschke ML, Purwar AK, Qu H, Rak J, Rakotozafindrabe A, Ravinovich I, Read KF, Rembeczki S, Reygers K, Riabov V, Riabov Y, Richardson E, Roach D, Roche G, Rolnick SD, Rosati M, Rosen CA, Rosendahl SSE, Rosnet P, Rukoyatkin P, Ruzicka P, Rykov VL, Sahlmueller B, Saito N, Sakaguchi T, Sakai S, Sakashita K, Samsonov V, Sano S, Sato T, Sawada S, Sedgwick K, Seele J, Seidl R, Semenov AY, Semenov V, Seto R, Sharma D, Shein I, Shibata TA, Shigaki K, Shimomura M, Shoji K, Shukla P, Sickles A, Silva CL, Silvermyr D, Silvestre C, Sim KS, Singh BK, Singh CP, Singh V, Slunecka M, Soldatov A, Soltz RA, Sondheim WE, Sorensen SP, Sourikova IV, Sparks NA, Staley F, Stankus PW, Stenlund E, Stepanov M, Ster A, Stoll SP, Sugitate T, Suire C, Sukhanov A, Sziklai J, Takagui EM, Taketani A, Tanabe R, Tanaka Y, Tanida K, Tannenbaum MJ, Tarafdar S, Taranenko A, Tarján P, Themann H, Thomas TL, Togawa M, Toia A, Tomásek L, Tomita Y, Torii H, Towell RS, Tram VN, Tserruya I, Tsuchimoto Y, Vale C, Valle H, van Hecke HW, Vazquez-Zambrano E, Veicht A, Velkovska J, Vértesi R, Vinogradov AA, Virius M, Vrba V, Vznuzdaev E, Wang XR, Watanabe D, Watanabe K, Watanabe Y, Wei F, Wei R, Wessels J, White SN, Winter D, Wood JP, Woody CL, Wright RM, Wysocki M, Xie W, Yamaguchi YL, Yamaura K, Yang R, Yanovich A, Ying J, Yokkaichi S, Young GR, Younus I, You Z, Yushmanov IE, Zajc WA, Zaudtke O, Zhang C, Zhou S, Zolin L. Transition in yield and azimuthal shape modification in dihadron correlations in relativistic heavy ion collisions. PHYSICAL REVIEW LETTERS 2010; 104:252301. [PMID: 20867367 DOI: 10.1103/physrevlett.104.252301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/05/2010] [Indexed: 05/29/2023]
Abstract
Hard-scattered parton probes produced in collisions of large nuclei indicate large partonic energy loss, possibly with collective produced-medium response to the lost energy. We present measurements of π^{0} trigger particles at transverse momenta p{T}{t}=4-12 GeV/c and associated charged hadrons (p{T}{a}=0.5-7 GeV/c) vs relative azimuthal angle Δϕ in Au+Au and p+p collisions at sqrt[s{NN}]=200 GeV. The Au+Au distribution at low p{T}{a}, whose shape has been interpreted as a medium effect, is modified for p{T}{t}<7 GeV/c. At higher p{T}{t}, the data are consistent with unmodified or very weakly modified shapes, even for the lowest measured p{T}{a}, which quantitatively challenges some medium response models. The associated yield of hadrons opposing the trigger particle in Au+Au relative to p+p (I{AA}) is suppressed at high p{T} (I{AA}≈0.35-0.5), but less than for inclusive suppression (R{AA}≈0.2).
Collapse
|
143
|
Lee KS, Park I, Ro J, Kang HS, Kim SW, Lee S, Jung SY, Kwon Y. Phase IB study of primary chemotherapy with paclitaxel, gemcitabine, and sunitinib in patients with HER2-negative stage II/III breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
144
|
Han S, Ro J, Paquet A, Huang W, Weidler J, Lee KS, Park I, Oh D, Im S, Kim T. HER2, p95HER2, and HER3 expression and treatment outcome of lapatinib plus capecitabine in HER2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.1088] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
145
|
Keam B, Im S, Koh Y, Han S, Oh D, Kang K, Kim T, Park I, Noh D, Bang Y. Use of sequential FDG-PET/CT to guide extent of axillay lymph node dissection in breast cancer receiving neoadjuvant chemotherapy. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.588] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
146
|
Ghong TH, Han SH, Chung JM, Byun JS, Kim TJ, Aspnes DE, Kim YD, Park IH, Kim YW. Nondestructive analysis of coated periodic nanostructures from optical data. OPTICS LETTERS 2010; 35:733-735. [PMID: 20195335 DOI: 10.1364/ol.35.000733] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Optical data are essential for the accurate nondestructive determination of profiles of periodic structures in integrated-circuit technology. In rigorous coupled-wave analysis, the sample is generally modeled as layers consisting of a single material and the ambient. We extend present capabilities to the analysis of structures with overlayers and demonstrate our approach by determining quantitatively the thicknesses of top, sidewall, and bottom oxides of deliberately and naturally oxidized structures.
Collapse
|
147
|
Lee JY, Ha SR, Park IH, Lee SC, Cho JH. Characteristics of DOC concentration with storm density flows in a stratified dam reservoir. WATER SCIENCE AND TECHNOLOGY : A JOURNAL OF THE INTERNATIONAL ASSOCIATION ON WATER POLLUTION RESEARCH 2010; 62:2467-2476. [PMID: 21099032 DOI: 10.2166/wst.2010.537] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
Abstract
Among natural organic matter (NOM) defined as the complex matrix of organic materials abundant in natural waters, a gradual accumulation of recalcitrant organic matter (ROM) has been observed in impounded water bodies such as a lake or dam reservoir in spite of extensive efforts made to curtail organic pollutant loadings generated in their catchment areas. This paper aims to identify the effect of diffuse pollution resulting from allochthonous organic matters on the temporal and spatial characteristics of organic matters in a stratified dam reservoir, Daecheong Dam, using both intensive observation and CE-QUAL-W2 model simulation. With the limitation of observation data in terms of organic matters of inflow waters from boundary tributaries and impounded water in the reservoir, organic matter was represented by organic carbon including labile particular organic carbon (LPOC), refractory organic carbon (RPOC), labile dissolved organic carbon (LDOC), and refractory organic carbon (RDOC). Both autochthonous and allochthonous origins of organic carbon were considered in the modeling of eutrophication of the reservoir water using CE-QUAL-W2. The result of simulation during the period from 2001 to 2005 was observed to be a gradual accumulation of particular organic carbon (POC). It is clear that the model calculation results enable the explanation of the internal and external movement of constituents in the reservoir. In particular turbidity and NOM were well related in the upper region of the reservoir according to flow distance, gradually changing to dissolved form of organic matter, DOC affected organic matter concentration of reservoir water quality compared to turbidity.
Collapse
|
148
|
Kim S, Ro J, Park I, Lee K, Jeong J. Significance of Viral Reactivation in Hepatitis B Virus Carriers with Early Breast Cancer Receiving Anthracycline- or Taxane-Containing Chemotherapy. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-1113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background :It is known that cancer patients in healthy hepatitis B viral (HBV) carrier status are prone to develop hepatic dysfunction during cytotoxic chemotherapy. The objectives of this study were to determine the frequency of healthy HBV carrier status and subsequent viral reactivation resulting in hepatic dysfunction during cytotoxic chemotherapy, and its significance in early breast cancer patients.Methods :Among 3,433 patients with operable breast cancer diagnosed at the National Cancer Center, Korea between January 2001 and March 2009, 3,337 patients were tested for HBsAg. Retrospectively, medical records were reviewed for 139 (4.2%) patients who were positive for HBs Ag.Results :Of 139 patients, 112 patients received anthracycline or taxane based neoadjuvant (n=25) or adjuvant (n=87) combination chemotherapy. Prophylactic lamivudine therapy was administered in 33 patients (29.5%).Thirty of 112 (26.8%) patients developed reactivation of HBV with deterioration of hepatic function during chemotherapy. The rate of reactivaton was not different with or without further taxane therapy (43% vs. 44%, p=0.408).Although there was no significant difference in the rate of chemotherapy delay between two groups, the incidence of early termination of planned chemotherapy was higher in B viral reactivation group (23.3% vs. 4.9%, p=0.008). Within a median follow-up duration of 39 mo (range 1 mo to 95 mo), the rate of disease recurrence was comparable between two groups (10% vs. 18.3%, p=0.390).Lamivudine prophylaxis decreased the rate of HBV reactivation without statistical significance (15.1% vs. 35.4%, p=0.101). Despite more patients without prophylaxis developed G 3/4 AST/ALT elevation (40% vs. 84%, p=0.068), the majority of patients recovered to G 1/2 AST/ALT level within 12 months with anti-viral or supportive treatment (0% vs. 14.3%, p=1.00). One patient without lamivudine prophylaxis developed fulminant hepatic failure after 3rd cycles of neo-adjuvant chemotherapy and received living donor liver transplantation. After that, she received radical mastectomy and maintained adjuvant anti-hormonal therapy.Conclusions :Although lamivudine prophylaxis in HBV healthy carrier decreased the rate of viral reactivation during neo- or adjuvant chemotherapy, the majority of patients irrespective of prophylaxis recovered hepatic function in a year with conservative treatment. Early detection and intensive supportive care are as important as anti-viral prophylaxis in HBV healthy carrier when treated with cytotoxic chemotherapy.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1113.
Collapse
|
149
|
Jung S, Min S, Lee S, Park C, Kwon Y, Kim E, Ko K, Lee K, Park I, Jeong J, Shin K, Lee S, Kim S, Kang H, Ro J. Prognostic Factors for Locoregional Recurrence in Operable Breast Cancer Patients Treated with Preoperative Systemic Chemotherapy. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-1095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: We aimed to evaluate the clinicopathologic factors affecting locoregional recurrence (LRR) in potentially operable breast cancer patients receiving preoperative systemic chemotherapy (PST).Methods: We reviewed the records of 316 breast cancer patients treated with PST (doxorubicin/cyclophosphamide, 101; docetaxel /capecitabine, 103; paclitaxel/gemcitabine, 43; doxorubicin/docetaxel, 69) followed by surgery and adjuvant radiotherapy between 2002 and 2006. The majority of patients had clinical positive axillary lymph nodes. To define the prognostic factors for LRR, age, clinical stage, hormone receptor (HR) and HER2 status, clinical and pathologic response, type of operation, pathological characteristics including tumor size, tumor grade, nodal status, number of positive axillary nodes, size of metastatic lymph node and status of resection margin and tumor multiplicity before and after PST were analyzed.Results: Overall 52 patients (16.5%) in the primary tumor and 87 patients (27.5%) in the axillary nodes achieved a pathologic complete response (pCR), and 206 patients (65.2%) underwent breast conserving surgery (BCS). With a median follow-up of 52.4 month (range: 4.7 - 89.4), total 18 (5.7%) patients developed LRR; 2 of 110 (1.8%) patients with mastectomy vs. 16 of 206 (7.7%) patients with BCS (p=0.04). Other significant factors in the univariate analysis were clinical T stage, HR status, clinical response and tumor multiplicity. A pCR in the primary tumor or node was not a prognostic factor for LRR in this study. In multivariate analysis, clinical T stage (T3/4, HR 7.8; 95% CI, 2.33-26.24; P=0.001), hormone receptor status (negative, HR 6.2; 95% CI, 1.91-20.22; P=0.002) and type of surgery (BCS, HR 9.5; 95% CI, 1.97-46.37; P=0.005) were independent prognostic factors. Among patients with BCS, advanced clinical T stage (HR 12.4; 95% CI, 3.45-44.56; P<0.001), negative hormone receptor (HR 4.74; 95% CI, 1.33-16.96; P=0.02), non-responding disease (HR 6.54; 95% CI, 1.07-40.12; P=0.04) and multiple tumors (HR 4.36; 95% CI, 1.06-17.90; P=0.04) developed more frequent LRR.Conclusions: Significantly more patients with advanced clinical T stage, negative HR status and BCS developed LRR in operable breast cancer treated with PST. Moreover, in patients with BCS after PST, clinically non-responding disease and multiple tumors showed unfavorable prognosis besides the larger tumors and negative hormone receptor.Partly supported by NCC Grant No 0610240
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 1095.
Collapse
|
150
|
Kim S, Baek N, Kwon B, Kwon Y, Ro J, Park I, Lee E. New HER2 Assay Using Trastuzumab for the Selection of Trastuzumab Responding Breast Cancer: The Positivity Is Significantly Associated with Pathologic Complete Response after Preoperative Chemotherapy. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-6050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:The evaluation of HER2 status is required for trastuzumab therapy in breast cancer. Although there are a few methods for an evaluation of HER2 status, theoretically the better method would be to check trastuzumab uptake itself in the tumor after trastuzumab administration. Therefore, we developed a different HER2 test (QHerceptest) using trastuzumab to improve an accuracy in the selection of patient for trastuzumab therapy.Patients and Methods:31 patients with HER2 positive (IHC 3+: 19 and IHC 2+ with FISH positive: 12) early breast cancer who were enrolled in a phase II preoperative paclitaxel, gemcitabin and trastuzumab (PGH) combination chemotherapy trial were evaluated. The pre-chemotherapy tumor specimens were obtained from the breast mass (n=24) or metastatic lymph nodes (n=7). After completing 6 cycles of PGH therapy, all patients underwent breast conserving surgery or mastectomy. We applied trastuzumab and Quantum dot conjugated goat anti-human IgG (QD-IgG, 655nm, Invitrogen) in the process of immunuhistochemistry for HER2 using formalin-fixed paraffin embedded specimen. After antigen retrieval, trastuzuamb was applied followed by QD-IgG. The result of QHerceptest was scored as negative, weak positive, moderate positive, or strong positive, and its relative uptake (RU) were quantified by imaging analysis program (Q-IHC, http://www.bio-miblab.org).Results:The uptake of trastuzumab by QHerceptest was heterogenous, varying between 1.3% to 193.7%. Twenty one of 31 (67.7%) patients achieved pathologic complete response (pCR): 11 of 12 patients (91.7%) with QHerceptest strong positive tumors, 6 of 9 patients (66.7%) with QHerceptest moderate positive tumors, and 4 of 7 patients (57.1%) with QHerceptest weak positive tumors, and none of 3 patients (9.4%) with QHerceptest negative tumors (p=0.0203). Besides, RU was significantly different between non-pCR and pCR groups (43.9±38.3, 80.8±47.1, p=0.0396)Conclusion:We developed a new HER2 assay using trastuzumab and applied to clinical specimen. This assay showed heterogenous trastuzumab uptake in this patient population. Although the data need to be verified by further study, the assay could possibly eliminate patients among HER2 positive breast cancer who will not get benefit by trastuzumab .This study was supported by NCC Grant No 0710292-2 and NCC Grant No 0610240.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 6050.
Collapse
|